Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Beximco Pharmaceuticals Limited Sponsored GDR RegS ( (GB:BXP) ) is now available.
Beximco Pharmaceuticals PLC has announced that it will miss the 31 December 2025 deadline to publish its audited annual results and Annual Report for the year ended 30 June 2025, triggering a temporary suspension of trading in its Global Depositary Receipts on London’s AIM from 2 January 2026 under AIM Rule 19. The delay stems from the Board’s inability to convene and approve the accounts while a Bangladesh Securities and Exchange Commission order to appoint nine additional independent non-executive directors remains unresolved in the High Court, which has gone into recess and must restart the case before a newly restructured bench; the company expects a decision no earlier than January 2026, after which it anticipates publishing its results and seeing the AIM suspension lifted, while its shares continue to trade uninterrupted on the Dhaka and Chittagong stock exchanges.
More about Beximco Pharmaceuticals Limited Sponsored GDR RegS
Beximco Pharmaceuticals PLC is a leading Bangladesh-based manufacturer and exporter of generic medicines and active pharmaceutical ingredients, offering a broad portfolio that spans tablets, capsules, liquids, semi-solids, injectables, inhalers, ophthalmic drops, insulins, and other advanced delivery systems. The company operates state-of-the-art, globally certified manufacturing facilities and serves more than 50 international markets, while also providing contract manufacturing services for multinational and global generic drug companies.
Average Trading Volume: 79,142
Technical Sentiment Signal: Buy
See more data about BXP stock on TipRanks’ Stock Analysis page.